Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Cocrystal Pharma, Inc. on February 24, 2017, covering events occurring between February 8, 2017, and February 23, 2017. The filing addresses significant changes in the company's executive leadership, specifically the appointment of an interim Chief Financial Officer (CFO).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed relates to executive compensation: the new interim CFO will be compensated at a rate of $125 per hour, with a maximum cap of $7,500 per week.
Material Changes
- Appointment of Interim CFO: On February 23, 2017, the Company entered into an agreement with James J. Martin to serve as interim CFO, effective February 27, 2017.
- Withdrawal of Prior Candidate: On February 8, 2017, the Company had agreed to appoint Craig Hooson as interim CFO. However, Mr. Hooson withdrew his acceptance on February 17, 2017, prior to commencing work.
- Leadership Continuity: The report notes that Gary Wilcox serves as the Interim Chief Executive Officer.
Management Commentary and Risks
The filing highlights a disruption in the search for permanent or interim financial leadership, necessitating a second appointment within a two-week period. Mr. Martin brings extensive experience, having served as CFO for Non-Invasive Monitoring Systems, Inc., Motus GI Holdings, Inc., VBI Vaccines Inc., Vapor Corp, Inc., and SafeStitch. No specific risks, contingencies, or unusual items beyond the leadership transition are detailed in this report.
Investor Verification Checklist
- Verify the start date and terms of James J. Martin's consulting agreement (Exhibit 10.1).
- Confirm the status of the search for a permanent CFO following the withdrawal of Craig Hooson.
- Review recent press releases or other filings for updates on the company's cash position, given the lack of financial data in this specific 8-K.
- Assess the impact of the interim CFO transition on the company's ongoing financial reporting and operational stability.